1092476-38-4

Basic information

• Product Name: (+/-)-N'-(3,5-dichlorophenyl)-2-(4-fluoro-1-naphthalenyl)-2-(4-methyl-1-piperazinyl)ethanohydrazide
• Synonyms: (+/-)-N'-(3,5-dichlorophenyl)-2-(4-fluoro-1-naphthalenyl)-2-(4-methyl-1-piperazinyl)ethanohydrazide
• CAS NO: 1092476-38-4
• Molecular Weight: 461.366
• Mol File: 1092476-38-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (+/-)-N'-(3,5-dichlorophenyl)-2-(4-fluoro-1-naphthalenyl)-2-(4-methyl-1-piperazinyl)ethanohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-N'-(3,5-dichlorophenyl)-2-(4-fluoro-1-naphthalenyl)-2-(4-methyl-1-piperazinyl)ethanohydrazide(1092476-38-4)
• EPA Substance Registry System: (+/-)-N'-(3,5-dichlorophenyl)-2-(4-fluoro-1-naphthalenyl)-2-(4-methyl-1-piperazinyl)ethanohydrazide(1092476-38-4)

Safety Data

• Hazardous Substances Data: 1092476-38-4(Hazardous Substances Data)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 182344-25-8 (4-fluoronaphthalen-1-yl)boronic acid 
• 1092477-63-8 (+/-)-(4-fluoro-1-naphthalenyl)(4-methyl-1-piperazinyl)acetic acid hydrochloride 
• 39943-56-1 3,5-dichlorophenylhydrazine 

Relevant articles and documents

N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: each R1 is independently selected from the group consisting of Cl, Br, CH3 and CF3; X is carbon or nitrogen; R1a is H or a straight C1-3 alkyl group; R2a is H or a methyl group R2 is selected from the group consisting of C1-3alkyl, H and -(CH2)n-, wherein n is 3 or 4 and the terminal carbon of the chain is bonded to the carbon atom adjacent to the nitrogen bearing the R2 group, such that a fused 6,5 or 6,6-bicyclic ring is formed. Y is selected from the group consisting of: phenyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, C1-3alkoxy, halogen, C1-3alkyl substituted by 1 to 7 fluoro atoms and C1-3alkoxy substituted by 1 to 7 fluoro atoms; pyridyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, OCH3, CF3, CN, and halogen; naphthyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of F and OCH3; pyrimidinyl; imidazo[1,2-a]pyridine-6-yl; benzothiophen-2-yl; benzothiophen-5-yl; benzofuran-2-yl; dibenzo[b,d]furan-3-yl; dibenzo[b,d]thiophen-2-yl; dibenzo[b,d]thiophen-4-yl; 1,3- benzodioxol-5-yl; 2,3-dihydro-1,4-benzodioxin-5-yl; 2,3-dihydro-1,4-benzodioxin-6-yl; 2,3- dihydro-1-benzofuran-4-yl; 2,2-difluoro-1,3-benzodiox-4-yl; pyridazinyl; imidazolyl; oxazolyl; pyrazolyl; thiazolyl; and triazolyl; with the proviso that when Y is 2,3-dihydro-1,4-benzodioxin-6-yl, R1 is not Cl; processes for their preparation, intermediates useble in these processes, pharmaceutical compositions containing them and their use in therapy, for example as modulators of of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.